Compare Salesforce Inc (CRM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Twist Bioscience Corp — how do they compare? Salesforce Inc trades at $228.61 (market cap $187.48B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Salesforce Inc is far larger — about 18.6× Twist Bioscience Corp's market cap, and Salesforce Inc pays a 0.77% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Twist Bioscience Corp for 27 Days on average.
| CRM | TWST | |
|---|---|---|
Market Cap | $187.48B | $10.08B |
Volume | 6,155,822 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $266.23 | $205.00 |
52-Week Low | $150.12 | $25.45 |
Typical Hold Time | 89 Days | 27 Days |
Enterprise Value | $217.82B | $10.01B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected) and robust profitability (77.28% gross margin, 21.99% net margin). Technical indicators signal bearish momentum with resistance at $227 and support at $222. Recent news highlights AI-driven volatility but also underscores Salesforce's positioning as an Agentic AI beneficiary.
Outlook: Salesforce's discounted valuation (P/E 20.86 vs. historical averages) and AI monetization growth (Agentforce ARR up 200% YoY) present a buying opportunity, though near-term risks include sector-wide pressure and macroeconomic uncertainty. Analyst consensus remains strongly bullish with a $271.91 price target, suggesting ~21% upside.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
